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ARTICLE OPEN
SFPQ promotes an oncogenic transcriptomic state
in melanoma
O. Bi1, C. A. Anene2, J. Nsengimana 3, M. Shelton1, W. Roberts4, J. Newton-Bishop5 and J. R. Boyne 1✉
© Crown 2021
The multifunctional protein, splicing factor, proline- and glutamine-rich (SFPQ) has been implicated in numerous cancers often due
to interaction with coding and non-coding RNAs, however, its role in melanoma remains unclear. We report that knockdown of
SFPQ expression in melanoma cells decelerates several cancer-associated cell phenotypes, including cell growth, migration,
epithelial to mesenchymal transition, apoptosis, and glycolysis. RIP-seq analysis revealed that the SFPQ-RNA interactome is
reprogrammed in melanoma cells and specifically enriched with key melanoma-associated coding and long non-coding transcripts,
including SOX10, AMIGO2 and LINC00511 and in most cases SFPQ is required for the efficient expression of these genes. Functional
analysis of two SFPQ-enriched lncRNA, LINC00511 and LINC01234, demonstrated that these genes independently contribute to the
melanoma phenotype and a more detailed analysis of LINC00511 indicated that this occurs in part via modulation of the miR-625-
5p/PKM2 axis. Importantly, analysis of a large clinical cohort revealed that elevated expression of SFPQ in primary melanoma
tumours may have utility as a prognostic biomarker. Together, these data suggest that SFPQ is an important driver of melanoma,
likely due to SFPQ–RNA interactions promoting the expression of numerous oncogenic transcripts.
Oncogene (2021) 40:5192–5203; https://doi.org/10.1038/s41388-021-01912-4
INTRODUCTION
At the molecular level, melanoma comprises a heterogeneous
group of disorders that harbour distinct aberrations in diverse
cellular processes [1–3]. Such heterogeneity suggests that multiple
mechanisms are involved in disease aetiology, and this is reflected
in the contribution of both different mutations and differential
gene and protein expression associated with melanoma transfor-
mation and progression [4].
Splicing factor proline- and glutamine-rich (SFPQ) is a multi-
functional DNA- and RNA-binding protein that regulates numer-
ous cellular mechanisms, including RNA-processing, transcription,
DNA damage response and innate immunity [5–9]. Aberrant SFPQ
function is associated with the aetiology of neurodegenerative
disorders [10–12] and colorectal [13], hepatocellular [14], renal
[15], Chronic Myeloid Leukaemia [16] and prostate cancer [17].
Intriguingly, it appears that SFPQ-long non-coding RNA (lncRNA)
interactions are responsible for pathological changes in numerous
cancers [14, 15, 18] including breast [19, 20] and ovarian tumours
[21]. Despite comprising a family of up to 90,000 transcripts [22],
the majority of lncRNAs are incompletely annotated and remain
poorly understood at the functional level. However, dysregulated
expression of lncRNA has been shown to correlate with poor
outcome across a range on neoplasms, with increasing numbers
of lncRNA being implicated in driving metastasis [23–25].
Here we investigated the role of SFPQ in melanoma cells and
showed that expression of SFPQ contributes to melanoma cell
growth, migration, apoptosis, glycolysis, and epithelial to
mesenchymal transition (EMT). Investigation and interrogation of
the SFPQ-RNA interactome in primary melanocytes compared
with melanoma cells via RNA-immunoprecipitations (RIP)-seq
revealed a dramatic reprogramming in melanoma that favoured
coding and non-coding transcripts associated with the promotion
of metastatic disease. Furthermore, knockdown of SFPQ led to a
significant decrease in many of these enriched transcripts,
including the lncRNA, LINC00511, which we showed contributes
to the melanoma cell phenotype. Finally, analysis of our
melanoma patient data revealed that high levels of SFPQ
expression in tumours negatively correlate with patient survival,
suggesting that SFPQ may have utility as a prognostic biomarker.
RESULTS
SFPQ knockdown decelerates cancer cell phenotype in
melanoma
To investigate the role of SFPQ in melanoma, we analysed SFPQ
protein expression in untransformed primary human melanocytes
(PM) alongside a range of melanoma cell lines. As can be seen in
Fig. 1a, we observed a significant increase in SFPQ expression in
each melanoma cell line compared with PM. SFPQ has been
identified as an essential melanoma gene in a CRISPR genome-
wide loss of function screen [26], and analysis of this dataset
revealed that melanoma cell lines (n= 46) show high dependency
(DEMETER2 scores) on SFPQ regardless of its expression (i.e., poor
correlation between dependency score and expression levels) (Fig.
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1b). Together, these data suggest that SFPQ may actively drive
melanoma development. To test this, we explored if SFPQ
expression was required for ‘cancer cell phenotypes’, in vitro,
including increased cell growth, cell migration, EMT and
decreased apoptosis and oxidative phosphorylation (OXPHOS).
To this end, SFPQ expression was knocked down using SFPQ-
specific GapmeR antisense oligonucleotides (ASOs) and decreased
levels of SFPQ mRNA and protein confirmed via qRT-PCR and
western blot, respectively (Fig. 1c). The impact of SFPQ knock-
down on viable cell growth (Fig. 1d), cell death (Fig. 1e) and cell
migration (Fig. 1f) was then determined and in each case, we
observed a significant shift away from a cancer cell phenotype.
Given the importance of dysregulated respiration in melanoma
biology we also investigated if SFPQ knockdown affected cellular
respiration via real-time analysis of oxygen consumption rate
(OCR). Data in Fig. 1g show that knockdown of SFPQ led to a
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significant decrease in basal respiration, maximal respiration, ATP
production and spare respiration capacity, suggesting impaired
OXPHOS in cells with decreased expression of SFPQ. Finally, we
investigated the impact of SFPQ knockdown and overexpression
on several EMT markers and observed a decrease in the
expression of mesenchymal markers following knockdown of
SFPQ and an increase in cells where SFPQ expression was
increased (Fig. 1h). Together, these data demonstrate that
knockdown of SFPQ in melanoma cells results in a wide-ranging
attenuation of the cancer cell phenotype.
Comparative analysis of SFPQ-RNA interactome in primary
melanocytes and melanoma cells
Given data demonstrating a role for SFPQ in melanoma cell
phenotype, we were keen to characterise the SFPQ-RNA
interactome in PM and establish if this was reprogrammed in
melanoma cells. To this end, PM and A2058 melanoma cells were
lysed, and RIP performed using either an SFPQ-specific antibody
or IgG-antibody isotype control (Fig. S1A), followed by analysis via
RNA-seq. Initially, we identified all transcripts that were (i)
significantly enriched with SFPQ in PM compared with A2058
cells; (ii) enriched with SFPQ in both PM and A2058 cells; (iii)
significantly enriched with SFPQ in A2058 cells compared with PM
(Fig. 2a). Most SFPQ-enriched transcripts comprised mRNAs, with
8124 unique peaks called, however, further analysis revealed 345
SFPQ–lncRNA interactions across both cell backgrounds (Fig. 2b).
We observed significant differential enrichment of both mRNA
and lncRNA transcripts between PM and A2058 cells and while the
RNA biotype with shared enrichment included significantly more
genes, the non-coding RNA (ncRNA) biotype was more significant
in A2058, suggesting specific reprogramming of SFPQ–lncRNA
interactions in melanoma. (Fig. 2c). To determine if baseline
expression of these differentially enriched genes in PM and A2058
transcriptomes was influencing SFPQ interaction, whole-cell RNA
expression profiles were integrated with RIP-Seq data with
unsupervised clustering. We observed no association between
whole-cell RNA transcript abundance and the specificity of the
SFPQ–RNA interactions (Fig. 2d and Fig. S1B). Gene ontology (GO)
analysis was then performed to identify enriched biological
processes for PM-specific and A2058-specific SFPQ–mRNA inter-
actors, respectively. Interestingly, PM-specific targets were sig-
nificantly enriched for GO terms broadly associated with
extracellular matrix (ECM) organisation, whereas A2058-specific
targets were significantly associated with GO terms relating to the
positive regulation of the cell cycle (Fig. 2e).
Given the widely documented relationship between SFPQ and
lncRNAs in several cancers, including melanoma, SFPQ interactors
were also ranked according to their PM- and A2058-specificity (Fig.
2f, g). Discerning the functional importance of enriched lncRNA
gene lists from RNA-seq studies such as the one reported here is
problematic, as the vast majority of lncRNAs remain functionally
uncharacterised. However, it is interesting to note that the most
PM-specific SFPQ-lncRNA interactors included genes associated
with tumour suppressor function, such as EMX2OS and FENDRR
[27, 28], whereas the most A2058-specific SFPQ-lncRNA interactors
comprise genes widely reported as oncogenic, such as LINC00511
[29–31]. We next sought to validate the top hits from our A2058
RIP-seq data in additional melanoma cell lines. To this end, SFPQ
RIPs were performed using cell lysate isolated from the M14 and
UACC-62 melanoma cell lines and enrichment with SFPQ assessed
via qRT-PCR. As can be seen in Fig. 2h, the top mRNA and lncRNA
targets enriched with SFPQ in the A2058 dataset were also
significantly enriched with SFPQ in M14 and UACC-62 cells,
whereas transcripts that were not present in our RIP-seq dataset
did not exhibit significant enrichment with SFPQ. Collectively,
these data show that compared with PM, SFPQ-RNA interactions
in melanoma cells are reprogrammed and skewed towards
oncogenic coding and non-coding transcripts.
SFPQ-enriched melanoma-specific lncRNA contribute to the
cancer phenotype
RIP-seq analysis identified 137 lncRNA that is enriched with SFPQ
in A2058 melanoma cells. To establish if any novel melanoma-
specific SFPQ-enriched lncRNA were functionally important for the
cancer phenotype, we opted to investigate two SFPQ-enriched
genes, LINC00511 and LINC01234, which have recently been
implicated in the progression of cancer, but to date have not been
associated with melanoma. Initially, A2058 cells were transfected
with either control, LINC00511- or LINC01234-specific GapmeR
ASOs and knockdown of target transcript levels confirmed via
qRT-PCR (Fig. 3a). We observed a marked reduction in LINC00511-
depleted viable cell growth over 72 h and a lesser, but still
significant reduction in growth kinetics following knockdown of
LINC01234 (Fig. 3b). Interestingly, caspase 3/7 activity was
significantly increased following knockdown of LINC00511, but
not in LINC01234-depleted cells (Fig. 3c). In contrast, we observed
a significant decrease in cell migration following knockdown of
either LINC00511 or LINC01234 (Figs. 3d, e). Finally, whereas
knockdown of LINC01234 had little impact on cellular respiration,
LINC00511-depleted A2058 cells exhibited nominal but significant
decreases for basal and maximal respiration, ATP-linked respira-
tion, and spare respiration capacity (Fig. 3f).
LINC00511-miR-625-5p-PKM2 axis promotes glycolysis in
melanoma
Given the pronounced effect of LINC00511 knockdown in A2058
cells on cancer cell phenotype, we decided to investigate this
gene further. To this end, publicly available Ago2-CLIP data [32]
was analysed to identify miRNAs that interact with LINC00511 and
miR-625-5p identified as the top interactor (Fig. 4a), an observa-
tion supported by several recent articles demonstrating that
LINC00511 directly sponges miR-625-5p in renal, gastric and lung
cancer [33–35]. To investigate if LINC00511 is functioning to
sponge miR-625-5p in melanoma, LINC00511 was knocked down
in A2058 cells, as described above, and miR-625-5p expression
analysed via miRCURY LNA miRNA PCR Assay. As can be seen in
Fig. 1 SFPQ expression promotes the cancer phenotype in melanoma. a Total protein was isolated from primary melanocytes (PM) and
melanoma cell lines prior to analysis of SFPQ expression via immunoblot, n= 3. b SFPQ dependency score (x-axis) was compared with SFPQ
expression levels (y-axis) in melanoma cell lines. Within the plot, lower DEMETER2 scores correspond to more dependency on SFPQ, and
positive values indicate no dependence. c Total RNA was extracted from A2058 cells transiently transfected with SFPQ-specific GapmeR or
control for 24, 48 and 72 h prior to generation of cDNA and analysis of SFPQ expression via qPCR, n= 3. d Viable growth of A2058 cells
transiently transfected with the indicated GapmeR and cultured for 24, 48 and 72 h was determined using CellTitre-Glo®, n= 3. e A2058 cells
were transiently transfected with SFPQ-specific GapmeR or control and cultured for 48 h prior to staining with Annexin V-FITC and Propridium
iodide and analysis via FACS, n= 3. f A2058 cells were transfected with SFPQ-specific GapmeR or control and cultured for 48 h prior to analysis
of cell migration via wound healing (left panel) and transwell (right panel) assay, n= 3. g A2058 cells were transfected with SFPQ-specific
GapmeR or control and cultured for 48 h prior to analysis of cellular respiration using the Cell Mito Stress Test kit, n= 3. h A2058 cells were
transiently transfected with SFPQ-specific GapmeRs, pFLAG-SFPQ, or corresponding scramble GapmeR and parent vector controls and
cultured for 48 h, prior to isolation of total protein and RNA and analysis of indicated EMT markers via western blot and qRT-PCR, respectively,
n= 3.
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Fig. 4b, depletion of LINC00511 led to a significant increase in miR-
625-5p transcript level, compared with control and knockdown of
LINC01234, suggesting that LINC00511 may sponge miR-625-5p in
melanoma cells. Recently, miR-625-5p was reported to target the
PKM2 isoform of pyruvate kinase in melanoma to attenuate
glucose consumption. To explore if LINC00511 knockdown led to a
decrease in the expression of PKM2, LINC00511-depleted A2058
melanoma cells were analysed via qRT-PCR and a significant
decrease in PKM2 expression was observed, whereas no decrease
in PKM2 expression was seen in either SFPQ- or LINC01234-
depleted cells (Fig. 4c and Fig. S2). Consistently, analysis of the
TCGA-melanoma dataset demonstrated that amplification of
LINC00511 significantly increased the expression of PKM2 (Fig.4d).
To investigate if the decrease in PKM2 transcripts was due to
impaired LINC00511-mediated sponging of miR-625-5p,
LINC00511-depleted cells were co-transfected with miR-625-5p-
specific inhibitor or scramble control and PKM2 expression
assessed, as described above. As can be seen in Fig. 4e,
transfection with miR-625-5p inhibitor restored PKM2 transcript
abundance following LINC00511 knockdown. Next, we utilised
Seahorse XF analysis to determine if inhibition of miR-625-5p
rescued the decrease in OCR in LINC00511-depleted cells. Data in
O. Bi et al.
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Fig. 4f show that co-transfection of LINC00511 and miR-625-5p
inhibitor led to a partial but significant rescue of the diminished
basal and maximal OCR observed following LINC00511 knock-
down. Together, these data demonstrate that expression of
LINC00511 in melanoma regulates the miR-625-5p/PKM2 axis,
which may explain LINC00511-dependent changes to OCR in
A2058 melanoma cells.
SFPQ regulates the expression of RNA interactors
To determine if SFPQ regulates the transcript levels of interacting
RNAs in melanoma, SFPQ expression was knocked down in A2058
cells and expression of several SFPQ-enriched mRNA and lncRNA
genes determined via qRT-PCR. As can be seen in Fig. 5a, knockdown
of SFPQ led to a significant decrease in the transcript abundance of
several, but not all, SFPQ-enriched RNAs. Specifically, we observed
approximately two-fold reduction in SOX10 and MAGEA3 transcript
levels, but no reduction in the levels of AMIGO2 or any of the three
reference genes used to normalise qRT-PCR data (GAPDH, RPS13 and
TBP). Interestingly, we also observed significant reductions in the
transcript abundance of LINC00511, LINC01234 and TMEM51-AS1,
which represented the top three SFPQ-enriched lncRNA genes by cell
type specificity, however, we did not detect any change in the
expression of the melanoma-specific lncRNA, SAMMSON, which was
not enriched with SFPQ in our RIP-seq dataset. Similarly, over-
expression of SFPQ resulted in significant increases to LINC00511 and
LINC01234 transcript levels, but no change in the levels of SAMMSON
(Fig. S3). To assess if observed changes in SFPQ-enriched transcript
levels following knockdown of SFPQ were related to post-
transcriptional regulation, SFPQ was depleted and RNA Pol II activity
inhibited via treatment with actinomycin D, prior to analysis of target
gene transcript levels over a 6 h period. Only SOX10 and TMEM51-AS1
exhibited decreased stability in SFPQ-depleted cells (Fig. 5b). To gain
a better understanding of how SFPQ might be regulating the
expression of enriched RNAs, SFPQ-enriched transcript regions were
identified and annotated, and Integrative Genomics Viewer utilised
to visualise coverage of the reads across the identified genes. Global
analysis of SFPQ peaks revealed a similar profile in PM and A2058
melanoma cells, with most binding occurring at exon–intron
boundaries and towards the 3′end of transcripts (Fig. 5c and Fig.
S4). Together, these data demonstrate that SFPQ contributes to the
efficient expression of several melanoma-associated oncogenic
transcripts in a predominantly RNA stability-independent manner,
and by doing so contributes to the maintenance of a ‘cancer
transcriptomic state’ in melanoma cells, in vitro.
SFPQ is a potential prognostic biomarker for melanoma
Analysis of data detailing SFPQ expression in normal skin
compared with nevi, primary and metastatic melanoma
(GSE46517) was carried out and revealed that SFPQ expression
is significantly increased in metastatic tumours compared with
control and primary tumour samples (Fig. 6a). However, SFPQ
expression groups (stratified by expression quantiles) were not
associated with patient survival in the TCGA-melanoma dataset
(Fig. 6b). To investigate if SFPQ expression groups in primary
melanoma tumours were prognostic for survival, we utilised our
previously published transcriptomic data from the primary
melanomas of 703 patients, which comprises part of the Leeds
Melanoma Cohort (LMC) [36]. Analysis of this cohort revealed that
primary tumour expression of SFPQ significantly predicted patient
survival with reduced survival for patients in the top three
quartiles compared with the lowest quartile (Fig. 6c). Unfortu-
nately, the HT12.4 array utilised does not contain probes for any of
the melanoma-specific SFQP-enriched lncRNA described in this
study, preventing analysis of LINC00511 and LINC01234 expression
and patient survival in primary melanoma. Although less relevant,
two PM-specific SFPQ lncRNA interactors were available for
analysis in the LMC cohort and interestingly their expression
was positively associated with patient survival (Fig. S5). To
determine if SFPQ expression correlated with expression of
LINC00511 and LINC01234 in melanoma tumours, we analysed
TCGA-melanoma datasets on the GEPIA2 web portal [37] and
found significant correlation between the expression of SFPQ and
LINC00511 (r= 0.14, p= 0.0027), and SFPQ and LINC01234 (r=
0.24, p= 2.2−07) (Fig. 6d), suggesting that these lncRNAs are
positively associated with SFPQ. Together, these data demonstrate
that increased expression of SFPQ in primary melanoma is
associated with decreased melanoma patient survival and that
SFPQ expression may have some utility as prognostic biomarker in
primary melanoma.
DISCUSSION
The precise role of SFPQ in cancer is complex and appears to be
tissue specific. For example, in breast and prostate cancer SFPQ
appears to be an important driver of the cancer phenotype via
post-transcriptional regulation of key genes such as oestrogen
receptor α (ERα) and androgen receptor (AR), respectively [17, 20].
Whereas in colorectal, lung and renal cancer SFPQ has been
reported to act as a transcriptional repressor that serves to
dampen proto-oncogene expression, a function that is frequently
derailed via the overexpression and binding of oncogenic
lncRNAs, such as MALAT-1 [38] and SANT1 [15]. The role of SFPQ
in melanoma is less clear, with a single article suggesting SFPQ
attenuates RAB23 expression via binding of the lncRNA, LLME23
[39]. Interestingly, we did not detect the LLME23 transcript in our
A2058 RIP-seq dataset. Indeed, the LLME23 transcript remains
incompletely annotated and is unlisted as a lncRNA in both the
NCBI 109.20200815 and Ensembl 101 genome releases, casting
some doubt on the nature of this gene.
Fig. 2 SFPQ–RNA interactome is reprogrammed in A2058 melanoma cells. a Pie chart depicts the proportion of all interaction RNA
transcripts shared between PM and A2058, specific to PM or specific to A2058. b Pie chart depicts the proportion of non-coding interacting
RNA transcripts shared between PM and A2058, specific to PM or specific to A2058. c Heatmap of expression profile of all identified lncRNA
interactors across IgG control and SFPQ-IP. Within the heatmap, orange colour indicates enrichment in SFPQ-IP compared to IgG and white
colour indicates no enrichment. d Heat map of relative expression profile of identified lncRNA interactors across whole-cell RNA (A2058 and
PM), IgG control and SFPQ-IP. Within the heatmap, red colour indicates high expression relative to whole-cell RNA and blue colour indicates low
expression (left panel). Distribution plots SFPQ-specific interactions against cell-type expression levels. Within the plot, the left panel (white box)
is the total number of SFPQ interactors, middle panel (Cell) indicates the proportion of SFPQ interactors in terms of cell-specific expression. The
right panel (SFPQ) shows the distribution of SFPQ-specific interactions by cell type (upper right panel). A2058 and PM data were analysed to
determine the fold-increase in relative cell expression compared with fold-increase in relative SFPQ-enrichment for the A2058-specific SFPQ-
enriched lncRNAs, LINC00511 and LINC01234 (lower right panel). e Cluster comparison plot of enriched biological processes for transcripts
shared between PM and A2058, specific to PM or specific to A2058. Gene ratio genes in ontology/total gene set and FDR false discovery rate.
f SFPQ-enriched mRNA transcripts were ranked based on the specificity of enrichment in either PM or A2058 melanoma cells. g SFPQ-enriched
lncRNA transcripts were ranked based on the specificity of enrichment in either PM or A2058 melanoma cells. h SFPQ-RNA interactions
identified in A2058 via RIP-seq were confirmed via RNA-IP and qRT-PCR in M14 and UACC-62 melanoma cells, n= 3.
O. Bi et al.
5196
Oncogene (2021) 40:5192 – 5203
Data in Fig. 1b–f suggest that the net functional output of SFPQ
expression in melanoma cell lines is oncogenic. This hypothesis is
supported by studies in hormone-refractory prostate cancer, where
increased SFPQ expression has been reported to drive expression
of AR transcripts, in addition to other key driver genes, to promote
disease progression (17). RIP-seq analysis demonstrated that the
SFPQ-RNA interactomes of PM and melanoma cells diverged
significantly and, crucially, in a manner that was not simply
associated with relative transcript abundance (Fig. 2c), which can
be a limitation of RIP-seq, suggesting that these differences were
due to reprogramming. Interestingly, gene-level analysis of SFPQ-
enriched mRNA transcripts exclusively associated with PM revealed
several targets that are frequently downregulated in melanoma
and specifically associated with ECM architecture (COL1A2,
COL3A1, Decorin, and Fubilin-1) (40), in addition to the proapop-
totic tumour suppressor gene, DPP4, which has been reported as a
suppressor of metastatic progression in melanoma [40]. In contrast,
the top SFPQ-enriched mRNA transcripts in melanoma cells were
generally associated with disease progression, such as AMIGO2,
MAGEA3, MAGEA1, and the transcription factor, SOX10 [41–45].
A similar story emerged when we compared lncRNA enriched
with SFPQ in PM and melanoma cell backgrounds. The SFPQ-
enriched lncRNA transcripts most specific to PM were EMX2OS and
FENDRR, the latter reported to function as a tumour suppressor in
most cancers, including melanoma [27, 46–49]. The function of
EMX2OS in cancer differs depending on cell background [28, 50].
Fig. 3 LINC00511 and LINC01234 contribute to the cancer phenotype in A2058 melanoma cells. a Total RNA was extracted from A2058 cells
transiently transfected with the indicated GapmeR for 48 h prior to generation of cDNA and analysis of target gene expression via qPCR, n= 3.
b Viable growth of A2058 cells transiently transfected with the indicated GapmeR and cultured for 24, 48 and 72 h was determined using
CellTitre-Glo®, n= 3. c A2058 cells were transiently transfected with the indicated GapmeR and cultured for 48 h prior to addition of the
Caspase-Glo® 3/7 reagent. Plates were incubated at room temperature for 30min and luminescence recorded, n= 3. d A2058 cells were
transfected with the indicated GapmeR and cultured for 48 h prior to analysis of cell migration via wound healing assay, n= 3. e A2058 cells
were transfected with the indicated GapmeR and cultured for 48 h prior to analysis of cell migration via transwell assay, n= 3 f A2058 cells were
transfected with the indicated GapmeR and cultured for 48 h prior to analysis of cellular respiration using the Cell Mito Stress Test kit, n= 3.
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We observed a downregulation of EMX2OS in several melanoma
cell lines, compared with PM (Fig. S5). Moreover, analysis of LMC
patient data demonstrated an inverse relationship between
EMX2OS expression and tumour thickness, mitotic rate, and
survival (Fig. S5), suggesting that this lncRNA may function as a
tumour suppressor in melanoma. In contrast, A2058-specific SFPQ-
enriched lncRNA included LINC00511, DUXAP8, TMEM51-AS1,
FOXD2-AS1 and LINC01234, all of which have been shown to drive
metastasis in a range of cancers via various mechanisms
[29, 30, 51–55], however, only FOXD2-AS1 has been associated
previously with melanoma [54].
Our analysis of two SFPQ-enriched lncRNAs, LINC00511 and
LINC01234, both with established roles as oncogenes in other
cancer backgrounds, revealed that knockdown of these genes
impaired melanoma viable cell growth, migration and, in the case
of LINC00511, cellular respiration (Fig. 3b–f). Recently, LINC00511
was reported to accumulate in both nuclear and cytoplasmic
fractions [33], suggesting that this lncRNA may possess sponging
activity. We demonstrated that LINC00511 expression is inversely
correlated with miR-625-5p transcript levels (Fig. 4b) and that
disruption of the LINC00511/miR-625-5p axis resulted in decreased
expression of PKM2 (Fig. 4c–e), presumably via its well-defined role
in regulating glycolytic flux [56]. PKM2 was absent from the list of
SFPQ-enriched transcripts in our RIP-seq data and SFPQ knock-
down had no impact on PKM expression or exon 9–10 splicing
(Fig. 4c and Fig. S2), suggesting that it does not regulate
alternative splicing of PKM. This result was somewhat unexpected,
as SFPQ knockdown does reduce the expression of LINC00511 (Fig.
5a). This observation may relate to partial knockdown of SFPQ
protein (~50%) via ASO-transfection, which resulted in an ~40%
decrease in LINC00511 transcript levels (Fig. 5a) compared with the
~97% knockdown achieved by directly targeting LINC00511 with
Fig. 4 LINC00511/miR-625-5p/PKM2 axis regulates cellular respiration in A2058 melanoma cells. a Analysis of HITS-CLIP-seq data identified
miR-625-5p as a LINC00511 interaction partner. b Total RNA was extracted from A2058 cells transiently transfected with the indicated GapmeR
for 48 h prior to generation of cDNA and analysis of target gene expression via qPCR (LINC00511 and LINC01234) and miRCURY LNA miRNA
PCR (miR-625-5p), n= 3. c Total RNA was extracted from A2058 cells transiently transfected with the indicated GapmeR for 48 h prior to
generation of cDNA and analysis of PKM2 expression via qPCR, n= 3. d TCGA-melanoma datasets were analysed to determine the impact of
LINC00511 CNV amplification on PKM2 expression e Total RNA was extracted from A2058 cells transiently co-transfected with the indicated
GapmeR alongside either miR-625-5p-specific miRCURY LNA power inhibitor or control for 48 h prior to generation of cDNA and analysis of
PKM2 expression via qPCR, n= 3. f A2058 cells were transiently co-transfected with the indicated GapmeR alongside either miR-625-5p-
specific miRCURY LNA power inhibitor or control for 48 h prior to analysis of cellular respiration using the Cell Mito Stress Test kit, n= 3.
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Fig. 5 SFPQ enhances the expression of target RNAs. a Total RNA was extracted from A2058 cells transiently transfected with SFPQ-specific
GapmeR or control for 48 h prior to generation of cDNA and analysis of target gene expression via qPCR, n= 3. b A2058 cells were transiently
transfected with SFPQ-specific GapmeR or control for 48 h prior to the addition of actinomycin D (1 μg/ml). Total RNA was isolated from
treated cells at 3 and 6 h, cDNA generated and used to analyse target genes via qPCR, n= 3. c ChIPseeker R package was used to annotate
SFPQ enrichment on exon, intron, UTR, intergenic and promoter regions and data processed via the Integrative Genomics Viewer (IGV) to
visualise the coverage of the reads across the identified genes.
O. Bi et al.
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ASOs (Fig. 4b). Therefore, it seems possible that while SFPQ
knockdown leads to a significant decrease in the expression of
LINC00511, this is not sufficient to dysregulate the LINC00511/miR-
625-5p axis and thus does not impact on PKM2 expression.
Our observation that melanoma-specific SFPQ-enriched genes
were significantly decreased following SFPQ knockdown (Fig. 5a) and
increased in cells overexpressing FLAG-SFPQ (Fig. S3) supports a role
for SFPQ in efficient expression of bound-transcripts, rather than
endogenous post-transcriptional processing events. Indeed, a recent
article demonstrating that diminished availability of splicing factors in
the nucleoplasm attenuates transcript release from the parent gene
[57] provides a model whereby SFPQ may positively contribute to
target RNA expression, a hypothesis that is particularly appealing
given that SFPQ is a key regulator of transcriptional termination [58].
A second model, that is not mutually exclusive, is that SFPQ may
regulate the expression of bound RNAs via increased stabilisation of
the transcript. SFPQ has been previously shown to regulate the
stability of AR transcripts in prostate cancer and neurons and our
own analysis of SFPQ-enriched transcripts identify SOX10 and the
lncRNA, TMEM51-AS1 as being destabilised in SFPQ depleted cells
(Fig. 5b). How SFPQ mediates transcript stability remains unclear, but
one possibility is that SFPQ shields bound RNAs from degradation, in
a manner analogous to other RNA-binding proteins (RBP), such as
Human antigen R (HuR) [59, 60] or the La-related protein superfamily
[61, 62].
Analysis of a large population-based melanoma cohort demon-
strated that melanoma patients with increased expression of SFPQ
in primary tumours were significantly more likely to die due to
their disease (Fig. 6c). However, while SFPQ expression was
significantly increased in metastatic melanoma, compared with
primary tumours (Fig. 6a), analysis of TCGA-melanoma datasets
showed that differential expression of SFPQ in metastatic disease
was not associated with patient survival (Fig. 6b). There are several
differences between the LMC and TCGA cohorts. The most
obvious is that LMC tumours are all primaries at different AJCC
stages (~35% stage I, 50% stage II and 15% stage III) while TCGA’s
are mostly metastases (>80%). Moreover, LMC samples are
population based (patients were recruited as they came into
clinic), while TCGA samples are selected. Finally, in the LMC cohort
cause of death and subsequently analysed survival was exclusive
to melanoma-associated deaths. Thus, the different results
observed in the LMC and TCGA datasets suggest that high
expression of SFPQ in primary tumours might be a driver of
disease progression and thus have some utility as a prognostic
biomarker, but at late-stage disease, further increases in SFPQ
expression are less significant.
In summary, we have shown that SFPQ positively contributes to
the cancer phenotype in melanoma, likely via reprograming of the
SFPQ-RNA interactome in melanoma to favour the expression of
oncogenic transcripts. It will be interesting to determine the
global impact of SFPQ knockout on RNA expression in melanoma,
particularly given recent work in renal cancer demonstrating that
RBPs have a wide-ranging impact on RNA expression programs
and by extension the cancer transcriptome [63].
MATERIALS AND METHODS
Tissue culture
Immortalised cell lines were obtained from European Collection of
Authenticated Cell Cultures and certified mycoplasma-free. UACC-62 and
A375 cells were maintained in Minimum Essential Medium, M14 in Roswell
Park Memorial Institute 1640 Medium (RPMI), and A2058 cells in Dulbecco’s
Modified Eagle Medium, in each case supplemented with 10% foetal
bovine serum, 100 U/ml of penicillin and 100 µg/ml of streptomycin.
Primary human melanocytes (CELLnTEC, Switzerland) were grown in a 2:1
Fig. 6 Increased expression of SFPQ in primary melanoma is associated with decreased melanoma patient survival. a GEO data
(GSE46517) was analysed to determine SFPQ mRNA expression in normal skin, benign nevi, primary and metastatic melanoma. b SFPQ
expression did not associate with patient survival in TCGA-melanoma datasets. c Patients with lower SFPQ expression in primary tumours
have an improved melanoma-specific survival in the LMC. Data presented in quartiles, q1–q4. d Expression correlation was analysed for SFPQ,
LINC00511 and LINC01234 using TCGA-melanoma datasets on the GEPIA2 web portal.
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mixture of keratinocyte serum-free media (K-SFM) and Eagle’s minimal
essential medium supplemented with 25 µg/ml bovine pituitary extract,
0.2 ng/ml rEGF, penicillin (100 U/ml), streptomycin (100 µg/ml) and 2mM L-
glutamine. All cells were cultured at 37 °C and 5% CO2. LNA inhibitors were
transfected into cells using HiPerfect (QIAgen, UK), as previously described
[64]. Details of LNA inhibitors used in this study can be found in Table S1,
pSFPQ-FLAG has been previously described [65].
Cell migration
For wound healing assays scratches were generated in a confluent cell
sheet using a 200 μl pipette tip and cells cultured in SFM. Images of each
wound were captured over 24 h (EVOS XL Core Cell Imaging System, 4×
objective) and wound closure measured using the MRI tool (Image J).
Transwell migration assays were carried out in 8 µm inserts (Starstedt,
Germany) and migrated cells stained using 0.2% (w/v) crystal violet (Fisher
Science, UK), imaged (EVOS XL Core Cell Imaging System) and the number
of migrated cells calculated, as previously described [66].
Viable cell growth
Cells were seeded at a density of 1 × 104 cells/well in white-walled 96-well
plates (ThermoFisher, UK). After 24 h, media was replaced with 100 μl of
SFM and cells incubated at 37 °C for a further 24, 48 and 72 h with viable
cell growth assessed at each time point using CellTiterGlo Luminescent
Cell Viability Assay (Promega, UK) and luminescence recorded 10min after
reagent addition using the GloMax® Explorer system (Promega, UK).
Apoptosis
Apoptosis and cell death was analysed via FACS using the Guava®
easyCyte™ Flow Cytometer (Luminex, US), as described elsewhere [67]. For
analysis of caspase 3/7 activity, cells were seeded at a density of 1 × 104
cells/well, cultured for 24 h prior to addition of 100 μl of Caspase-Glo® 3/7
reagent directly to cells, incubation for 1 h at RT and recording of
luminescence using the GloMax® Explorer system (Promega, UK).
Analysis of cellular respiration
OCR was determined using the Mito Stress Test Kit and XFe96 Extracellular
Flux Analyzer (Seahorse Bioscience, Billerica, MA, USA). Cells were seeded
in Seahorse XF96 V3 PS Cell Culture Microplates (Agilent Technologies, UK).
Following incubation, cells were transferred to unbuffered XF assay media
at pH 7.4 supplemented with 25mM glucose and 1mM sodium pyruvate
and placed at 37 °C in a non-CO2 incubator for one hour prior to assay.
Cells were analysed using the Seahorse XF Cell Mito Stress Test (Agilent
Technologies, UK). Immediately following each run cells were lysed, and
protein concentration determined by Sulforhodamine B assay for normal-
isation. OCR was automatically calculated and analysed by the Seahorse
Wave software (Agilent Technologies, UK).
qRT-PCR
Total RNA was extracted from cells and 500 ng used to generate cDNA prior
to qRT-PCR analysis using SsoAdvanced SYBR master mix (Bio-Rad, UK) on the
CFX96 system (Bio-Rad, UK) normalised against TBP, RPS13 and GAPDH
reference genes, as described elsewhere (66). RNA stability assays were carried
out using 1 μg/ml actinomycin-D, as previously described [68]. Micro-RNA
expression was analysed using miRCURY LNA miRNA PCR assays (Qiagen, UK)
and data normalised against SNORD44 and SNORD48 reference genes. A list of
oligonucleotides used during this study can be found in Table S2.
RIP-seq
SFPQ-RNA immunoprecipitations were performed using SFPQ-specific
antibody or IgG control (Table S3) and the Magna RIP™ RNA-Binding
Protein Immunoprecipitation Kit (Merck Millipore, USA). Total RNA libraries
were prepared using TruSeq Stranded Total RNA Sample Prep Kit (Illumina,
USA) and the TruSeq cDNA libraries were analysed via NextSeq 500
(Illumina, USA) and data deposited at GEA (GSE171291). Details of RIP-seq
data analysis are available in Supplementary Methods.
Cell dependency analysis
Gene dependency data for 18120 across 54 Melanoma cell lines were
download from DepMap project (https://depmap.org/portal/). DEMETER2
inferred z-scores representing cell viability independent gene knockdown
effects and expression values were extracted for SFPQ.
Clinical data
The LMC transcriptomic data comprises 703 primaries profiled on Illumina
DASL array HT12.4 (EGAS00001002922, [36, 69]). Correlation between
tumour characteristics and tumour expression of targets was performed
via Spearman rank correlation. Data from TCGA-SKCM [70] were analysed
to determine the correlation between gene expression, copy number
alteration and patient clinical characteristics. These expressions were
further tested for association with melanoma-specific survival after their
split into quartiles by applying Cox proportional hazards regression and
plotting Kaplan-Meier survival curves. Where appropriate, certain quartiles
were combined to reduce the number of parameters. Both single gene
models and bivariate models were applied with an interaction term to test
the independence between genes. These analyses were conducted in
STATA v14 (StataCorp, TX, USA), or R using tools provided on the GEPIA2
web portal http://gepia2.cancer-pku.cn/#survival.
Statistical analysis
Except otherwise stated, graphical data shown represent mean ± standard
error of mean (SEM) using at least three independent experiments.
Differences between means was analysed by Student’s t test,
Mann–Whitney Wilcoxon test, Kruskal–Wallis test, or one-way ANOVA as
detailed in the figure legends. Survival analyses were conducted using the
Cox proportional hazards regression and Kaplan–Meier graphs with log-
rank test. Statistics was considered significant at p < 0.05.
REFERENCES
1. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009;27:3–9.
2. Ghosh P, Chin L. Genetics and genomics of melanoma. Expert Rev Dermatol.
2009;4:131.
3. Qiu T, Wang H, Wang Y, Zhang Y, Hui Q, Tao K. Identification of genes associated
with melanoma metastasis. Kaohsiung J Med Sci. 2015;31:553–61.
4. Djulbegovic MB, Uversky VN. Expanding the understanding of the heterogeneous
nature of melanoma with bioinformatics and disorder-based proteomics. Int J
Biol Macromol. 2020;150:1281–93.
5. Bottini S, Hamouda-Tekaya N, Mategot R, Zaragosi LE, Audebert S, Pisano S, et al.
Post-transcriptional gene silencing mediated by microRNAs is controlled by
nucleoplasmic Sfpq. Nat Commun. 2017;8:1189.
6. Imamura K, Imamachi N, Akizuki G, Kumakura M, Kawaguchi A, Nagata K, et al.
Long noncoding RNA NEAT1-dependent SFPQ relocation from promoter region
to paraspeckle mediates IL8 expression upon immune stimuli. Mol Cell.
2014;53:393–406.
7. Jaafar L, Li Z, Li S, Dynan WS. SFPQ*NONO and XLF function separately and
together to promote DNA double-strand break repair via canonical non-
homologous end joining. Nucleic Acids Res. 2017;45:1848–59.
8. Mora Gallardo C, Sánchez de Diego A, Gutiérrez Hernández J, Talavera-Gutiérrez
A, Fischer T, Martínez-A C, et al. Dido3-dependent SFPQ recruitment maintains
efficiency in mammalian alternative splicing. Nucleic Acids Res. 2019;47:5381–94.
9. Rajesh C, Baker DK, Pierce AJ, Pittman DL. The splicing-factor related protein
SFPQ/PSF interacts with RAD51D and is necessary for homology-directed repair
and sister chromatid cohesion. Nucleic Acids Res. 2011;39:132–45.
10. Ke YD, Dramiga J, Schütz U, Kril JJ, Ittner LM, Schröder H, et al. Tau-mediated
nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer’s and
Pick’s disease. PLoS ONE. 2012;7:e35678.
11. Lu J, Shu R, Zhu Y. Dysregulation and dislocation of SFPQ disturbed DNA orga-
nization in alzheimer’s disease and frontotemporal dementia. J Alzheimers Dis.
2018;61:1311–21.
12. Luisier R, Tyzack GE, Hall CE, Mitchell JS, Devine H, Taha DM, et al. Intron retention
and nuclear loss of SFPQ are molecular hallmarks of ALS. Nat Commun.
2018;9:2010.
13. Ji Q, Zhang L, Liu X, Zhou L, Wang W, Han Z, et al. Long non-coding RNA MALAT1
promotes tumour growth and metastasis in colorectal cancer through binding to
SFPQ and releasing oncogene PTBP2 from SFPQ/PTBP2 complex. Br J Cancer.
2014;111:736–48.
14. Hu Z, Dong L, Li S, Li Z, Qiao Y, Li Y, et al. Splicing regulator p54(nrb) /non-POU
domain-containing octamer-binding protein enhances carcinogenesis through
oncogenic isoform switch of MYC box-dependent interacting protein 1 in
hepatocellular carcinoma. Hepatology. 2020;72:548–68.
15. Gao Z, Chen M, Tian X, Chen L, Chen L, Zheng X, et al. A novel human lncRNA
SANT1 cis-regulates the expression of SLC47A2 by altering SFPQ/E2F1/HDAC1
binding to the promoter region in renal cell carcinoma. RNA Biol. 2019;16:940–9.
16. Zeng C, Liu S, Lu S, Yu X, Lai J, Wu Y, et al. The c-Myc-regulated lncRNA NEAT1
and paraspeckles modulate imatinib-induced apoptosis in CML cells. Mol Cancer.
2018;17:130.
O. Bi et al.
5201
Oncogene (2021) 40:5192 – 5203
17. Takayama KI, Suzuki T, Fujimura T, Yamada Y, Takahashi S, Homma Y, et al.
Dysregulation of spliceosome gene expression in advanced prostate cancer by
RNA-binding protein PSF. Proc Natl Acad Sci USA. 2017;114:10461–6.
18. Ru Y, Chen XJ, Guo WZ, Gao SG, Qi YJ, Chen P, et al. NEAT1_2-SFPQ axis mediates
cisplatin resistance in liver cancer cells in vitro. Onco Targets Ther.
2018;11:5695–702.
19. de Silva HC, Lin MZ, Phillips L, Martin JL, Baxter RC. IGFBP-3 interacts with NONO
and SFPQ in PARP-dependent DNA damage repair in triple-negative breast
cancer. Cell Mol Life Sci. 2019;76:2015–30.
20. Mitobe Y, Iino K, Takayama KI, Ikeda K, Suzuki T, Aogi K, et al. PSF promotes ER-
positive breast cancer progression via posttranscriptional regulation of ESR1 and
SCFD2. Cancer Res. 2020;80:2230–42.
21. Pellarin I, Dall’acqua A, Gambelli A, Pellizzari I, D’andrea S, Sonego M, et al.
Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum
response in ovarian cancer-modulating SRSF2 activity. Oncogene.
2020;39:4390–403.
22. Volders PJ, Verheggen K, Menschaert G, Vandepoele K, Martens L, Vandesompele
J, et al. An update on LNCipedia: a database for annotated human lncRNA
sequences. Nucleic Acids Res. 2015;43:4363–4.
23. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding
RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature.
2010;464:1071–6.
24. Hua JT, Ahmed M, Guo H, Zhang Y, Chen S, Soares F, et al. Risk SNP-mediated
promoter-enhancer switching drives prostate cancer through lncRNA PCAT19.
Cell. 2018;174:564–75.e518.
25. Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, et al. lncRNA epigenetic
landscape analysis identifies EPIC1 as an oncogenic lncRNA that Interacts with
MYC and promotes cell-cycle progression in cancer. Cancer Cell. 2018;33:706–20.
e709.
26. Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al.
Defining a cancer dependency map. Cell. 2017;170:564–76.e516.
27. Chen XE, Chen P, Chen S, Lu J, Ma T, Shi G, et al. Long non-coding RNA FENDRR
inhibits migration and invasion of cutaneous malignant melanoma cells. Biosci
Rep. 2020;40:40.
28. Gu Y, Feng C, Liu T, Zhang B, Yang L. The downregulation of lncRNA EMX2OS
might independently predict shorter recurrence-free survival of classical papillary
thyroid cancer. PLoS One. 2018;13:e0209338.
29. Sun CC, Li SJ, Li G, Hua RX, Zhou XH, Li DJ. Long intergenic noncoding RNA 00511
acts as an oncogene in non-small-cell lung cancer by binding to EZH2 and
suppressing p57. Mol Ther Nucleic Acids. 2016;5:e385.
30. Zhang J, Sui S, Wu H, Zhang J, Zhang X, Xu S, et al. The transcriptional landscape
of lncRNAs reveals the oncogenic function of LINC00511 in ER-negative breast
cancer. Cell Death Dis. 2019;10:599.
31. Zhu FY, Zhang SR, Wang LH, Wu WD, Zhao H. LINC00511 promotes the pro-
gression of non-small cell lung cancer through downregulating LATS2 and KLF2
by binding to EZH2 and LSD1. Eur Rev Med Pharmacol Sci. 2019;23:8377–90.
32. Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA,
miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq
data. Nucleic Acids Res. 2014;42:D92–97.
33. Chen Z, Wu H, Zhang Z, Li G, Liu B. LINC00511 accelerated the process of gastric
cancer by targeting miR-625-5p/NFIX axis. Cancer Cell Int. 2019;19:351.
34. Deng H, Huang C, Wang Y, Jiang H, Peng S, Zhao X. LINC00511 promotes the
malignant phenotype of clear cell renal cell carcinoma by sponging microRNA-
625 and thereby increasing cyclin D1 expression. Aging. 2019;11:5975–91.
35. Xue J, Zhang F. LncRNA LINC00511 plays an oncogenic role in lung adeno-
carcinoma by regulating PKM2 expression via sponging miR-625-5p. Thorac
Cancer. 2020;11:2570–9.
36. Muralidhar S, Filia A, Nsengimana J, Poźniak J, O’shea SJ, Diaz JM, et al. Vitamin D-
VDR signaling inhibits Wnt/beta-catenin-mediated melanoma progression and
promotes antitumor immunity. Cancer Res. 2019;79:5986–98.
37. Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-
scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:
W556–W560.
38. Hu L, Tang J, Huang X, Zhang T, Feng X. Hypoxia exposure upregulates MALAT-1
and regulates the transcriptional activity of PTB-associated splicing factor in A549
lung adenocarcinoma cells. Oncol Lett. 2018;16:294–300.
39. Wu CF, Tan GH, Ma CC, Li L. The non-coding RNA llme23 drives the malignant
property of human melanoma cells. J Genet Genomics. 2013;40:179–88.
40. Wesley UV, Albino AP, Tiwari S, Houghton AN. A role for dipeptidyl peptidase IV in
suppressing the malignant phenotype of melanocytic cells. J Exp Med.
1999;190:311–22.
41. Fontanals-Cirera B, Hasson D, Vardabasso C, Di Micco R, Agrawal P, Chowdhury A,
et al. Harnessing BET inhibitor sensitivity reveals AMIGO2 as a melanoma survival
gene. Mol Cell. 2017;68:731–44.e9.
42. Graf SA, Busch C, Bosserhoff AK, Besch R, Berking C. SOX10 promotes melanoma
cell invasion by regulating melanoma inhibitory activity. J Investig Dermatol.
2014;134:2212–20.
43. Roeder C, Schuler-Thurner B, Berchtold S, Vieth G, Driesch PV, Schuler G, et al.
MAGE-A3 is a frequent tumor antigen of metastasized melanoma. Arch Dermatol
Res. 2005;296:314–9.
44. Shakhova O, Zingg D, Schaefer SM, Hari L, Civenni G, Blunschi J, et al. Sox10
promotes the formation and maintenance of giant congenital naevi and mela-
noma. Nat Cell Biol. 2012;14:882–90.
45. Wang D, Wang J, Ding N, Li Y, Yang Y, Fang X, et al. MAGE-A1 promotes mela-
noma proliferation and migration through C-JUN activation. Biochem Biophys
Res Commun. 2016;473:959–65.
46. Li Y, Zhang W, Liu P, Xu Y, Tang L, Chen W, et al. Long non-coding RNA FENDRR
inhibits cell proliferation and is associated with good prognosis in breast cancer.
Onco Targets Ther. 2018;11:1403–12.
47. Wang B, Xian J, Zang J, Xiao L, Li Y, Sha M, et al. Long non-coding RNA FENDRR
inhibits proliferation and invasion of hepatocellular carcinoma by down-
regulating glypican-3 expression. Biochem Biophys Res Commun.
2019;509:143–7.
48. Zhang G, Han G, Zhang X, Yu Q, Li Z, Li Z, et al. Long non-coding RNA FENDRR
reduces prostate cancer malignancy by competitively binding miR-18a-5p with
RUNX1. Biomarkers. 2018;23:435–45.
49. Zhu Y, Zhang X, Wang L, Zhu X, Xia Z, Xu L, et al. FENDRR suppresses cervical
cancer proliferation and invasion by targeting miR-15a/b-5p and regulating
TUBA1A expression. Cancer Cell Int. 2020;20:152.
50. Duan M, Fang M, Wang C, Wang H, Li M. LncRNA EMX2OS induces proliferation,
invasion and sphere formation of ovarian cancer cells via regulating the miR-654-
3p/AKT3/PD-L1 axis. Cancer Manag Res. 2020;12:2141–54.
51. Chen Y, Zhao H, Li H, Feng X, Tang H, Qiu C, et al. LINC01234/MicroRNA-31-5p/
MAGEA3 axis mediates the proliferation and chemoresistance of hepatocellular
carcinoma cells. Mol Ther Nucleic Acids. 2020;19:168–78.
52. Hui L, Wang J, Zhang J, Long J. lncRNA TMEM51-AS1 and RUSC1-AS1 function as
ceRNAs for induction of laryngeal squamous cell carcinoma and prediction of
prognosis. PeerJ. 2019;7:e7456.
53. Lin MG, Hong YK, Zhang Y, Lin BB, He XJ. Mechanism of lncRNA DUXAP8 in
promoting proliferation of bladder cancer cells by regulating PTEN. Eur Rev Med
Pharmacol Sci. 2018;22:3370–7.
54. Ren W, Zhu Z, Wu L. FOXD2-AS1 correlates with the malignant status and reg-
ulates cell proliferation, migration, and invasion in cutaneous melanoma. J Cell
Biochem. 2019;120:5417–23.
55. Zhao X, Liu Y, Li Z, Zheng S, Wang Z, Li W, et al. Linc00511 acts as a competing
endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-
3p in pancreatic ductal adenocarcinoma. J Cell Mol Med. 2018;22:655–67.
56. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R,
et al. The M2 splice isoform of pyruvate kinase is important for cancer meta-
bolism and tumour growth. Nature. 2008;452:230–3.
57. Hochberg-Laufer H, Neufeld N, Brody Y, Nadav-Eliyahu S, Ben-Yishay R, Shav-Tal
Y. Availability of splicing factors in the nucleoplasm can regulate the release of
mRNA from the gene after transcription. PLoS Genet. 2019;15:e1008459.
58. Kaneko S, Rozenblatt-Rosen O, Meyerson M, Manley JL. The multifunctional
protein p54nrb/PSF recruits the exonuclease XRN2 to facilitate pre-mRNA 3’
processing and transcription termination. Genes Dev. 2007;21:1779–89.
59. Chai Y, Liu J, Zhang Z, Liu L. HuR-regulated lncRNA NEAT1 stability in tumor-
igenesis and progression of ovarian cancer. Cancer Med. 2016;5:1588–98.
60. Hu YP, Jin YP, Wu XS, Yang Y, Li YS, Li HF, et al. LncRNA-HGBC stabilized by HuR
promotes gallbladder cancer progression by regulating miR-502-3p/SET/AKT axis.
Mol Cancer. 2019;18:167.
61. Hopkins TG, Mura M, Al-Ashtal HA, Lahr RM, Abd-Latip N, Sweeney K, et al. The
RNA-binding protein LARP1 is a post-transcriptional regulator of survival and
tumorigenesis in ovarian cancer. Nucleic Acids Res. 2016;44:1227–46.
62. Shao R, Scully SJ Jr., Yan W, Bentley B, Mueller J, Brown C, et al. The novel lupus
antigen related protein acheron enhances the development of human breast
cancer. Int J Cancer. 2012;130:544–54.
63. Perron G, Jandaghi P, Solanki S, Safisamghabadi M, Storoz C, Karimzadeh M, et al.
A general framework for interrogation of mRNA stability programs identifies
RNA-binding proteins that govern cancer transcriptomes. Cell Rep.
2018;23:1639–50.
64. Anene C, Graham AM, Boyne J, Roberts W. Platelet microparticle delivered
microRNA-Let-7a promotes the angiogenic switch. Biochim Biophys Acta Mol
Basis Dis. 2018;1864:2633–43.
65. Snijders AP, Hautbergue GM, Bloom A, Williamson JC, Minshull TC, Phillips HL,
et al. Arginine methylation and citrullination of splicing factor proline- and
glutamine-rich (SFPQ/PSF) regulates its association with mRNA. RNA.
2015;21:347–59.
O. Bi et al.
5202
Oncogene (2021) 40:5192 – 5203
66. Akhbari P, Tobin D, Poterlowicz K, Roberts W, Boyne JR. MCV-miR-M1 Targets the
Host-Cell Immune Response Resulting in the Attenuation of Neutrophil Chemo-
taxis. J Investig Dermatol. 2018;138:2343–54.
67. Williamson AJ, Dibling BC, Boyne JR, Selby P, Burchill SA. Basic fibroblast growth
factor-induced cell death is effected through sustained activation of p38MAPK
and up-regulation of the death receptor p75NTR. J Biol Chem.
2004;279:47912–28.
68. Baquero-Perez B., Antanaviciute A., Yonchev I. D., Carr I. M., Wilson S. A., White-
house A. The Tudor SND1 protein is an m(6)A RNA reader essential for replication
of Kaposi’s sarcoma-associated herpesvirus. Elife. 2019;8:e47261.
69. Nsengimana J, Laye J, Filia A, O’shea S, Muralidhar S, Poźniak J, et al. beta-
Catenin-mediated immune evasion pathway frequently operates in primary
cutaneous melanomas. J Clin Investig. 2018;128:2048–63.
70. Cancer Genome Atlas N. Genomic classification of cutaneous melanoma. Cell.
2015;161:1681–96.
ACKNOWLEDGEMENTS
The authors would like to thank Dr. M.J. Thornton and Dr. S. Sikkink for assistance
with primary melanocyte cell culture and Prof. M. Dickman for providing the pSFPQ-
FLAG construct. This work was funded by a personal scholarship to OB by Mr. Shaukat
Ali, British Skin Foundation award to JRB (030/s/18) and MRC award MR/M019012/1
to JNB.
COMPETING INTERESTS
The authors declare no competing interests.
ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41388-021-01912-4.
Correspondence and requests for materials should be addressed to J.R.B.
Reprints and permission information is available at http://www.nature.com/
reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© Crown 2021
O. Bi et al.
5203
Oncogene (2021) 40:5192 – 5203
